67515-76-8

Basic information

• Product Name: 2-Pyridinecarboxylicacid,5-amino-,methylester(9CI)
• Synonyms: 2-Pyridinecarboxylicacid,5-amino-,methylester(9CI);Methyl 5-amino-pyridine-2-carboxylate;Methyl 5-amino-pyridine-2...;METHYL 5-AMINOPICOLINATE;2-Pyridinecarboxylic acid, 5-aMino-, Methyl ester;Methyl 5-amino-2-pyridinecarboxylate;5-Amino-2-(carbomethoxy)pyridine
• CAS NO: 67515-76-8
• Molecular Formula: C₇H₈N₂O₂
• Molecular Weight: 152.15
• Product Categories: GLYCINESCAFFOLD;CARBOXYLICESTER;Heterocycle-Pyridine series
• Mol File: 67515-76-8.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 333.651 °C at 760 mmHg
• Flash Point: 155.587 °C
• Appearance: /
• Density: 1.239 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.571
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.63±0.10(Predicted)
• CAS DataBase Reference: 2-Pyridinecarboxylicacid,5-amino-,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarboxylicacid,5-amino-,methylester(9CI)(67515-76-8)
• EPA Substance Registry System: 2-Pyridinecarboxylicacid,5-amino-,methylester(9CI)(67515-76-8)

Safety Data

• Hazardous Substances Data: 67515-76-8(Hazardous Substances Data)

Usage

Description

2-Pyridinecarboxylic acid, 5-amino-, methyl ester (9CI) is an organic compound that serves as an intermediate in the synthesis of various pharmaceutical compounds. It is characterized by the presence of a pyridine ring with a carboxylic acid group at the 2nd position and an amino group at the 5th position, with a methyl ester group attached to the carboxylic acid.

Uses

Used in Pharmaceutical Industry:
2-Pyridinecarboxylic acid, 5-amino-, methyl ester (9CI) is used as a key intermediate in the preparation of N-Hydroxypyridine-2-carboxamide, N-Hydroxypyridazine-3-carboxamide, and N-Hydroxypyrimidine-2-carboxamide derivatives. These derivatives act as Dihydroceramide desaturase-1 inhibitors, which are important targets for the development of drugs to treat various diseases, including cancer and neurodegenerative disorders. The inhibition of Dihydroceramide desaturase-1 can modulate cellular lipid metabolism and influence cell signaling pathways, offering potential therapeutic benefits.

InChI:InChI=1/C7H8N2O2/c1-11-7(10)6-3-2-5(8)4-9-6/h2-4H,8H2,1H3

Upstream product

• 29682-14-2 5-nitro-pyridine-2-carboxylic acid methyl ester 
• 67-56-1 methanol 
• 24242-20-4 5-amino-pyridine-2-carboxylic acid 
• 55338-73-3 5-amino-2-cyanopyridine 
• 60891-70-5 1,3-diethyl 2-(5-nitropyridin-2-yl)propanedioate 
• 4548-45-2 2-chloro-5-nitropyridine 
• 30651-24-2 5-nitropicolinic acid 

Downstream Products

• 67515-84-8 5-(3-fluoro-benzylideneamino)-pyridine-2-carboxylic acid methyl ester 
• 67516-51-2 5-(4-fluoro-benzoylamino)-pyridine-2-carboxylic acid methyl ester 
• 138815-76-6 5-(4-Methyl-benzoylamino)-pyridine-2-carboxylic acid methyl ester 
• 67536-83-8 methyl 5-<(3-chlorobenzylidene)amino>-2-pyridinecarboxylate 
• 67515-87-1 5-(3,4-dichloro-benzylideneamino)-pyridine-2-carboxylic acid methyl ester 
• 67515-82-6 5-benzylamino-pyridine-2-carboxylic acid 
• 67515-91-7 5-(m-chlorobenzylamino)-pyridine-2-carboxaldehyde 
• 67516-29-4 5-(3-Methyl-benzylamino)-pyridine-2-carboxylic acid 
• 67515-81-5 methyl 5-(benzylamino)picolinate 
• 67516-13-6 5-(3-phenyl-propylamino)-pyridine-2-carboxylic acid 
• 67515-86-0 5-(3-fluoro-benzylamino)-pyridine-2-carboxylic acid 
• 67515-90-6 5-(m-chlorobenzylamino)-pyridine-2-carbinol 
• 67516-30-7 5-[Methyl-(3-methyl-benzyl)-amino]-pyridine-2-carboxylic acid 

Relevant articles and documents

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

Targeting breast cancer stem cells by novel HDAC3-selective inhibitors

Although histone deacetylase (HDAC) inhibitors have been known to suppress the cancer stem cell (CSC) population in multiple types of cancer cells, it remains unclear which HDAC isoforms and corresponding mechanisms contribute to this anti-CSC activity. Pursuant to our previous finding that HDAC8 regulates CSCs in triple-negative breast cancer (TNBC) cells by targeting Notch1 stability, we investigated related pathways and found HDAC3 to be mechanistically linked to CSC homeostasis by increasing β-catenin expression through the Akt/GSK3β pathway. Accordingly, we used a pan-HDAC inhibitor, AR-42 (1), as a scaffold to develop HDAC3-selective inhibitors, obtaining the proof-of-concept with 18 and 28. These two derivatives exhibited high potency and isoform selectivity in HDAC3 inhibition. Equally important, they showed in vitro and/or in vivo efficacy in suppressing the CSC subpopulation of TNBC cells via the downregulation of β-catenin.